Surrozen, Inc.

Surrozen, Inc. is a biotechnology company focused on discovering and developing product candidates that selectively modulate the Wnt signaling pathway for tissue repair. The Wnt pathway plays a critical role in cell growth, differentiation, and regeneration. Surrozen's lead product candidates are antibody-based therapeutics targeting various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. Key candidates include SZN-814, which combines Frizzled 4 agonism and VEGF antagonism to treat diabetic macular edema, wet AMD, and retinopathy; SZN-8143, which adds IL-6 targeting for DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for retinal vascular diseases.

Surrozen, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol SRZN. The company trades in United States Dollars (USD). As a US-based company listed on a US exchange, its stock is accessible to investors through major brokerage platforms and is subject to the regulatory framework of the US Securities and Exchange Commission.

Surrozen operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use living organisms or their components to develop products and technologies, often for medical applications. Surrozen's focus on the Wnt pathway and antibody-based therapeutics places it in the biotech subsector dedicated to regenerative medicine and targeted therapies for chronic diseases.

Surrozen, Inc. is headquartered in South San Francisco, California, United States. The company primarily serves the US market but also engages in international collaborations. For instance, it has a collaboration and license agreement with Boehringer Ingelheim International GmbH, a German pharmaceutical company, to research and develop Fzd4 bi-specific antibodies. Additionally, it has a research collaboration with TCGFB, Inc. to discover antibody therapeutics for idiopathic pulmonary fibrosis. These partnerships indicate a global reach in research and development.

Surrozen's pipeline includes several antibody-based therapeutics targeting the Wnt pathway. SZN-814 combines Frizzled 4 (Fzd4) agonism and VEGF antagonism for diabetic macular edema, wet AMD, and retinopathy. SZN-8143 adds IL-6 targeting for similar indications plus uveitic macular edema. SZN-413 is a Fzd4 targeted bi-specific antibody for retinal vascular diseases. The company has a collaboration with Boehringer Ingelheim to develop Fzd4 bi-specific antibodies and a research agreement with TCGFB, Inc. for TGF-ß antibody therapeutics for idiopathic pulmonary fibrosis. These partnerships help advance its pipeline and share development risks.